Unclaimed brand
We are a genomic medicines company leading a step shift in how ocular diseases are treated. We are going beyond single gene correction therapies to deliver new treatments as quickly as possible to patients affected by Inherited Retinal Diseases (IRDs), regardless of genetic cause.
Liking this brand profile? Share this page
Hex Code
Color name
RGB
HSL
CMYK
#051452
Gulf Blue
5, 20, 82
228, 89, 17
94, 76, 0, 68
#071C64
Deep Sapphire
7, 28, 100
226, 87, 21
93, 72, 0, 61
#FFFFFF
White
255, 255, 255
0, 0, 100
0, 0, 0, 0
SparingVision is a clinical-stage genomic medicines company focused on preserving and restoring vision in people with blinding retinal diseases. Based in Paris, with a US presence in Cambridge, Massachusetts, the company is developing gene-agnostic gene therapies that aim to help patients regardless of the genetic cause of their condition. Its approach targets photoreceptors, the eye’s light-sensing cells, and seeks to use the retina’s natural visual pathways rather than replace cells or bypass those pathways.
SparingVision’s research and development programs address inherited retinal diseases, including retinitis pigmentosa, as well as dry age-related macular degeneration and geographic atrophy. Its investigational programs include SPVN06, a neuroprotective therapy intended to preserve sight and slow disease progression, and SPVN20, a neuroenhancement therapy designed to restore vision through the retina’s native pathway. The company’s broader goal is to preserve visual function, slow the progression of retinal disease, and potentially restore sight. SparingVision combines ophthalmic research expertise with drug-development capabilities to advance these treatments toward patients. Its therapies remain investigational.
Company type
Privately Held
Year founded
2016
Company size
11-50 employees
